each X is selected from the group consisting of a bond, -O- and -S-; and

each n is 0 or 1.

In one aspect there is provided a compound or pharmaceutically acceptable salt ~~or prodrug~~ thereof having the structure of formula I:



I

wherein:

R^1, R^2 and R^4 are independently selected from the group consisting of H, C_{1-9} alkyl, halide, $-N(R^{10})_2$, $-XR^{10}$, CN, $-OCF_3$ and $-CF_3$;

R^3 is selected from the group consisting of carbocyclylR^6, ~~heterocyclylR^6,~~ arylR^6, 3-pyridylR^6, pyrimidinylR^6, pyridazinylR^6, and pyrazinylR^6 ~~and heteroarylR^6~~;

~~with the proviso that when R^3 is heteroaryl, the heteroaryl is not selected from the group consisting of isoquinoline, 1H-pyrrolo[2,3-*c*]pyridine and tetrazole;~~

R^5 is selected from the group consisting of $-(C_{1-9}\text{ alkyl})_n$carbocyclyl$R^7$, -piperazinyl$R^7$, -tetrahydropyranyl$R^7$, -pyrrolidinyl$R^7$, -piperidinyl$R^7$, -aryl$R^7$, -3-pyridyl$R^7$, -pyrimidinyl$R^7$, -pyridazinyl$R^7$, -pyrazolyl$R^7$, -benzo[d][1,3]dioxolyl$R^7$, 2,3-dihydrobenzo[b][1,4]dioxinylR^7, and -pyrazinylR^7 ~~$-(C_{1-9}\text{ alkyl})_n$heterocyclyl$R^7$, $-(C_{1-9}\text{ alkyl})_n$aryl$R^7$ and $-(C_{1-9}\text{ alkyl})_n$heteroaryl$R^7$~~;

~~with the proviso that R^5 is not 4-pyridylR^7 when R^1, R^2 and R^4 are H, R^3 is selected from the group consisting of 3-pyridylR^6, 4-pyridylR^6, 2-pyridylR^6, phenylR^6, thiazoleR^6,~~



~~imidazoleR^6, pyrimidineR^6, oxazoleR^6,~~

~~and~~

~~, and R^6 and R^7 are both H;~~

~~with the proviso that R^5 is not $-(CH_2)(3\text{-pyridyl})R^7$ when R^1, R^2 and R^4 are H, R^3 is selected from the group consisting of 3-pyridylR^6, 4-pyridylR^6 and thiazoleR^6, and R^6 and R^7 are both H;~~

~~with the proviso that R^5 is not phenylR^7 when R^1, R^2 and R^4 are H, R^3 is 4-pyridylR^6 and R^6 and R^7 are both H;~~

with the proviso that R^3 is not 3-pyridylR^6 when R^1, R^2 and R^4 are H, R^5 is selected from the group consisting of phenylR^7,  ,  ,  ,  ,  ,  ,  , and  ,  and  , and R^6 and R^7 are both H;

~~with the proviso that R^3 is not oxazoleR^6 when R^1, R^2 and R^4 are H, R^5 is selected from the group consisting of~~  ~~and~~  ~~, and R^6 is H;~~

~~with the proviso that R^3 is not thiazoleR^6 when R^1, R^2 and R^4 are H, R^5 is selected from the group consisting of~~  ~~and~~ ~~, and R^6 is H;~~

each R^6 is 1-5 substituents each selected from the group consisting of H, $C_{1\text{-}9}$ alkyl, halide, amino, $-OCF_3$, $-CF_3$, -CN, $-XR^{10}$, $-(C_{1\text{-}9}\text{ alkyl})_n\text{carbocyclyl}R^8$, $-(C_{1\text{-}9}\text{ alkyl})_n\text{heterocyclyl}R^8$, $-(C_{1\text{-}9}\text{ alkyl})_n\text{aryl}R^8$, $-(C_{1\text{-}9}\text{ alkyl})_n\text{heteroaryl}R^8$, $-C(=O)R^{11}$, $-N(R^{10})C(=O)R^{11}$, $-(C_{1\text{-}9}\text{ alkyl})_nN(R^{10})_2$, $-(C_{1\text{-}9}\text{ alkyl})_nN(R^{10})SO_2R^{11}$ and $-SO_2R^{11}$;

each R^7 is 1-5 substituents each selected from the group consisting of H, $C_{1\text{-}9}$ alkyl, halide, amino, $-OCF_3$, $-CF_3$, -CN, $-XR^{10}$, $-(C_{1\text{-}9}\text{ alkyl})_n\text{carbocyclyl}R^9$, $-(C_{1\text{-}9}\text{ alkyl})_n\text{heterocyclyl}R^9$, $-(C_{1\text{-}9}\text{ alkyl})_n\text{aryl}R^9$, $-(C_{1\text{-}9}\text{ alkyl})_n\text{heteroaryl}R^9$, $-C(=O)R^{11}$, $-N(R^{10})C(=O)R^{11}$, $-(C_{1\text{-}9}\text{ alkyl})_nN(R^{10})_2$, ~~$-(C_{1\text{-}9}\text{ alkyl})_nN(R^{10})SO_2R^{11}$~~ and $-SO_2R^{11}$;

each R^8 is 1-5 substituents each selected from the group consisting of H, $C_{1\text{-}3}$ alkyl, halide, amino, OCF_3, $-CF_3$ -CN, $-XR^{12}$, $-C(=O)R^{13}$, $-N(R^{12})C(=O)R^{13}$, $-(C_{1\text{-}9}\text{ alkyl})_nN(R^{12})_2$, $-(C_{1\text{-}9}\text{ alkyl})_nN(R^{12})SO_2R^{13}$ and $-SO_2R^{13}$;

each R^9 is 1-5 substituents each selected from the group consisting of H, $C_{1\text{-}3}$ alkyl, halide, amino, $-OCF_3$, $-CF_3$ -CN, $-XR^{12}$, $-C(=O)R^{13}$, $-N(R^{12})C(=O)R^{13}$, $-(C_{1\text{-}9}\text{ alkyl})_nN(R^{12})_2$, $-(C_{1\text{-}9}\text{ alkyl})_nN(R^{12})SO_2R^{13}$ and $-SO_2R^{13}$;

each R^{10} is independently selected from the group consisting of H, C_{1-9} alkyl, -(C_{1-9} alkyl)$_n$N(R^{14})$_2$, -(C_{1-9} alkyl)$_n$carbocyclylR^8, -(C_{1-9} alkyl)$_n$heterocyclylR^8, -(C_{1-9} alkyl)$_n$arylR^8 and -(C_{1-9} alkyl)$_n$heteroarylR^8;

each R^{11} is independently selected from the group consisting of C_{1-9} alkyl, ~~-N(R^{14})$_2$,~~ -(C_{1-9} alkyl)$_n$carbocyclylR^8, -(C_{1-9} alkyl)$_n$heterocyclylR^8, -(C_{1-9} alkyl)$_n$arylR^8 and -(C_{1-9} alkyl)$_n$heteroarylR^8;

each R^{12} is independently selected from the group consisting of H, C_{1-9} alkyl, -(C_{1-9} alkyl)$_n$N(R^{14})$_2$, -(C_{1-9} alkyl)$_n$carbocyclyl, -(C_{1-9} alkyl)$_n$heterocyclyl, -(C_{1-9} alkyl)$_n$aryl and -(C_{1-9} alkyl)$_n$heteroaryl;

each R^{13} is independently selected from the group consisting of C_{1-9} alkyl, -N(R^{14})$_2$, -(C_{1-9} alkyl)$_n$carbocyclyl, -(C_{1-9} alkyl)$_n$heterocyclyl, -(C_{1-9} alkyl)$_n$aryl and -(C_{1-9} alkyl)$_n$heteroaryl;

each R^{14} is independently selected from the group consisting of H, C_{1-3} alkyl, carbocyclyl and aryl;

each X is selected from the group consisting of a bond, -O- and -S-; and

each n is 0 or 1.

In another aspect, there is provided a compound or pharmaceutically acceptable salt ~~or prodrug~~ thereof having the structure of formula **Ia**:



Ia

wherein:

R^3 is selected from the group consisting of arylR^6 and 3-pyridylR^6~~heteroarylR^6~~;

~~with the proviso that when R^3 is heteroaryl, the heteroaryl is not selected from the group consisting of isoquinoline, 1H-pyrrolo[2,3-c]pyridine and tetrazole;~~

R^5 is selected from the group consisting of ~~carbocyclylR^7, heterocyclylR^7,~~ -arylR^7, 3-pyridylR^7, -pyrimidinylR^7, -pyridazinylR^7, and -pyrazinylR^7 ~~heteroarylR^7, and -(C_{1-3} alkyl)heteroarylR^7~~;

~~with the proviso that R^5 is not 4-pyridylR^7 when R^3 is selected from the group consisting of 3-pyridylR^6, 4-pyridylR^6, 2-pyridylR^6, phenylR^6, thiazoleR^6, imidazoleR^6, pyrimidineR^6, oxazoleR^6,~~

~~            and , and R^6 and R^7 are both H;~~

~~with the proviso that R^5 is not $-(CH_2)(3\text{-pyridyl})R^7$ when R^3 is selected from the group consisting of 3-pyridylR^6, 4-pyridylR^6 and thiazoleR^6, and R^6 and R^7 are both H;~~

~~with the proviso that R^5 is not phenylR^7 when R^3 is 4-pyridylR^6 and R^6 and R^7 are both H;~~

~~with the proviso that R^3 is not 3-pyridylR^6 when R^5 is selected from the group consisting of~~

~~phenylR^7,             and , and R^6 and R^7 are both H;~~

~~with the proviso that R^3 is not oxazoleR^6 when R^5 is selected from the group consisting of~~

~~   and  , and R^6 is H;~~

~~with the proviso that R^3 is not thiazoleR^6 when R^5 is selected from the group consisting of~~

~~  and  , and R^6 is H;~~

with the proviso that R^3 is not 3-pyridylR^6 when R^1, R^2 and R^4 are H, R^5 is selected from the group consisting of phenylR^7,    , and  , and R^6 and R^7 are both H;

each R^6 is 1-2 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, $-OCF_3$, $-CF_3$, -CN, $-OR^{10}$, $-(C_{1-2}\text{ alkyl})\text{heterocyclyl}R^8$, $-\text{heterocyclyl}R^8$, $-(C_{1-2}\text{ alkyl})\text{aryl}R^8$, $-C(=O)R^{11}$, $-N(R^{10})C(=O)R^{11}$ and $-(C_{1-2}\text{ alkyl})N(R^{10})_2$;

each R^7 is 1-2 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, $-OCF_3$, $-CF_3$, -CN, $-OR^{10}$, $-(C_{1-2}\text{ alkyl})\text{heterocyclyl}R^9$, $-\text{heterocyclyl}R^9$, $-\text{aryl}R^9$, $-(C_{1-2}\text{ alkyl})\text{aryl}R^9$, $-C(=O)R^{11}$, $-N(R^{10})C(=O)R^{11}$, $-N(R^{10})_2$, $-(C_{1-2}\text{ alkyl})N(R^{10})_2$, $-N(R^{10})SO_2R^{11}$ and $-SO_2R^{11}$;

each R^8 is 1-2 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, OCF_3, $-CF_3$ –CN and $-OR^{12}$;

[0016a] In one aspect there is provided a use of at least one compound as defined herein, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a disorder or disease in which aberrant Wnt signaling is implicated in a patient.

[0016b] In another aspect, there is provided a use of at least one compound as defined herein, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a disease or disorder mediated by the Wnt pathway in a patient.

[0016c] In another aspect, there is provided a use of at least one compound according as defined herein, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a disease or disorder mediated by kinase activity in a patient.

[0016d] In another aspect, there is provided a use of at least one compound as defined herein, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for inhibiting the activity of a protein kinase receptor, wherein the medicament is to be contacted with the receptor.

[0016e] In another aspect, there is provided a use of at least one compound as defined herein, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a disease or disorder associated with aberrant cellular proliferation in a patient.

[0016f] In another aspect, there is provided a use of at least one compound as defined herein, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for preventing or reducing angiogenesis in a patient.

[0016g] In another aspect, there is provided a use of at least one compound as defined herein, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for preventing or reducing abnormal cellular proliferation in a patient.

[0016h] In another aspect, there is provided a use of a pharmaceutical composition comprising one or more of the compounds as defined herein for the manufacture of a medicament for treating a disease or disorder associated with aberrant cellular proliferation in a patient, wherein the medicament is to be administered with a pharmaceutically acceptable carrier and one or more other agents.

[0016i] In another aspect, there is provided compound having the structure of:







7h

 ,  ,  ,  ,

 ,  ,  ,  ,

 ,  ,  , and  , or a pharmaceutically acceptable salt thereof

WHAT IS CLAIMED IS:

1. A compound or pharmaceutically acceptable salt or prodrug thereof having the structure of formula I:



I

wherein:

R^1, R^2 and R^4 are independently selected from the group consisting of H, C_{1-9} alkyl, halide, $-N(R^{10})_2$, $-XR^{10}$, CN, $-OCF_3$ and $-CF_3$;

R^3 is selected from the group consisting of carbocyclylR^6, heterocyclylR^6, arylR^6 and heteroarylR^6;

with the proviso that when R^3 is heteroaryl, the heteroaryl is not selected from the group consisting of isoquinoline, 1H-pyrrolo[2,3-*c*]pyridine and tetrazole;

R^5 is selected from the group consisting of $-(C_{1-9}$ alkyl$)_n$carbocyclylR^7, $-(C_{1-9}$ alkyl$)_n$heterocyclylR^7, $-(C_{1-9}$ alkyl$)_n$arylR^7 and $-(C_{1-9}$ alkyl$)_n$heteroarylR^7;

with the proviso that R^5 is not 4-pyridylR^7 when R^1, R^2 and R^4 are H, R^3 is selected from the group consisting of 3-pyridylR^6, 4-pyridylR^6, 2-pyridylR^6, phenylR^6, thiazoleR^6, imidazoleR^6, pyrimidineR^6, oxazoleR^6,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , and  , and R^6 and R^7 are both H;

with the proviso that R^5 is not $-(CH_2)$(3-pyridyl)R^7 when R^1, R^2 and R^4 are H, R^3 is selected from the group consisting of 3-pyridylR^6, 4-pyridylR^6 and thiazoleR^6, and R^6 and R^7 are both H;

with the proviso that R^5 is not phenylR^7 when R^1, R^2 and R^4 are H, R^3 is 4-pyridylR^6 and R^6 and R^7 are both H;

with the proviso that R^3 is not 3-pyridylR^6 when R^1, R^2 and R^4 are H, R^5 is selected from the group consisting of phenylR^7,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  and  , and R^6 and R^7 are both H;

with the proviso that R^3 is not oxazoleR^6 when R^1, R^2 and R^4 are H, R^5 is selected from the group consisting of  ,  and  , and R^6 is H;

with the proviso that R^3 is not thiazoleR^6 when R^1, R^2 and R^4 are H, R^5 is selected from the group consisting of  and  , and R^6 is H;

each R^6 is 1-5 substituents each selected from the group consisting of H, $C_{1\text{-}9}$ alkyl, halide, amino, $-OCF_3$, $-CF_3$, -CN, $-XR^{10}$, $-(C_{1\text{-}9}$ alkyl$)_n$carbocyclylR^8, $-(C_{1\text{-}9}$ alkyl$)_n$heterocyclylR^8, $-(C_{1\text{-}9}$ alkyl$)_n$arylR^8, $-(C_{1\text{-}9}$ alkyl$)_n$heteroarylR^8, $-C(=O)R^{11}$, $-N(R^{10})C(=O)R^{11}$, $-(C_{1\text{-}9}$ alkyl$)_nN(R^{10})_2$, $-(C_{1\text{-}9}$ alkyl$)_nN(R^{10})SO_2R^{11}$ and $-SO_2R^{11}$;

each R^7 is 1-5 substituents each selected from the group consisting of H, $C_{1\text{-}9}$ alkyl, halide, amino, $-OCF_3$, $-CF_3$, -CN, $-XR^{10}$, $-(C_{1\text{-}9}$ alkyl$)_n$carbocyclylR^9, $-(C_{1\text{-}9}$ alkyl$)_n$heterocyclylR^9, $-(C_{1\text{-}9}$ alkyl$)_n$arylR^9, $-(C_{1\text{-}9}$ alkyl$)_n$heteroarylR^9, $-C(=O)R^{11}$, $-N(R^{10})C(=O)R^{11}$, $-(C_{1\text{-}9}$ alkyl$)_nN(R^{10})_2$, $-(C_{1\text{-}9}$ alkyl$)_nN(R^{10})SO_2R^{11}$ and $-SO_2R^{11}$;

each R^8 is 1-5 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, OCF_3, $-CF_3$ -CN, $-XR^{12}$, $-C(=O)R^{13}$, $-N(R^{12})C(=O)R^{13}$, $-(C_{1-9}$ alkyl$)_nN(R^{12})_2$, $-(C_{1-9}$ alkyl$)_nN(R^{12})SO_2R^{13}$ and $-SO_2R^{13}$;

each R^9 is 1-5 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, $-OCF_3$, $-CF_3$ -CN, $-XR^{12}$, $-C(=O)R^{13}$, $-N(R^{12})C(=O)R^{13}$, $-(C_{1-9}$ alkyl$)_nN(R^{12})_2$, $-(C_{1-9}$ alkyl$)_nN(R^{12})SO_2R^{13}$ and $-SO_2R^{13}$;

each R^{10} is independently selected from the group consisting of H, C_{1-9} alkyl, $-(C_{1-9}$ alkyl$)_nN(R^{14})_2$, $-(C_{1-9}$ alkyl$)_n$carbocyclylR^8, $-(C_{1-9}$ alkyl$)_n$heterocyclylR^8, $-(C_{1-9}$ alkyl$)_n$arylR^8 and $-(C_{1-9}$ alkyl$)_n$heteroarylR^8;

each R^{11} is independently selected from the group consisting of C_{1-9} alkyl, $-N(R^{14})_2$, $-(C_{1-9}$ alkyl$)_n$carbocyclylR^8, $-(C_{1-9}$ alkyl$)_n$heterocyclylR^8, $-(C_{1-9}$ alkyl$)_n$arylR^8 and $-(C_{1-9}$ alkyl$)_n$heteroarylR^8;

each R^{12} is independently selected from the group consisting of H, C_{1-9} alkyl, $-(C_{1-9}$ alkyl$)_nN(R^{14})_2$, $-(C_{1-9}$ alkyl$)_n$carbocyclyl, $-(C_{1-9}$ alkyl$)_n$heterocyclyl, $-(C_{1-9}$ alkyl$)_n$aryl and $-(C_{1-9}$ alkyl$)_n$heteroaryl;

each R^{13} is independently selected from the group consisting of C_{1-9} alkyl, $-N(R^{14})_2$, $-(C_{1-9}$ alkyl$)_n$carbocyclyl, $-(C_{1-9}$ alkyl$)_n$heterocyclyl, $-(C_{1-9}$ alkyl$)_n$aryl and $-(C_{1-9}$ alkyl$)_n$heteroaryl;

each R^{14} is independently selected from the group consisting of H, C_{1-3} alkyl, carbocyclyl and aryl;

each X is selected from the group consisting of a bond, -O- and -S-; and

each n is 0 or 1.

2. The compound of claim 1 wherein n is 0.

3. The compound of claim 1 wherein n is 1.

4. The compound of claim 1 wherein X is O.

5. The compound of claim 1 wherein R^1, R^2 and R^4 are H.

6. The compound of claim 1 wherein R^3 is –heteroarylR^6.

7. The compound of claim 6 wherein the heteroaryl is 3-pyridyl.

8. The compound of claim 6 wherein the heteroaryl is 5-pyrimidinyl.

9. The compound of claim 6 wherein the heteroaryl is 4-pyridazinyl.

10. The compound of claim 6 wherein R^6 is one substituent and is selected from the group consisting of H and $-N(R^9)C(=O)R^{10}$.

11. The compound of claim 1 wherein R^5 is –heteroarylR^7.

12. The compound of claim 11 wherein the heteroaryl is 3-pyridyl.

13. The compound of claim 11 wherein the heteroaryl is 5-pyrimidinyl.

14. The compound of claim 11 wherein the heteroaryl is 4-pyridazinyl.

15. The compound of claim 11 wherein R^7 is one substituent and is selected from the group consisting of H, halide, $-OCF_3$, $-CF_3$, $-(C_{1\text{-}9}\ \text{alkyl})_n\text{heterocyclyl}R^9$, $-(C_{1\text{-}9}\ \text{alkyl})_nN(R^{10})_2$, $-(C_{1\text{-}9}\ \text{alkyl})_nN(R^{10})SO_2R^{11}$ and $-N(R^{10})C(=O)R^{11}$.

16. A compound or pharmaceutically acceptable salt or prodrug thereof having the structure of formula **Ia**:



Ia

wherein:

R^3 is selected from the group consisting of arylR^6 and heteroarylR^6;

with the proviso that when R^3 is heteroaryl, the heteroaryl is not selected from the group consisting of isoquinoline, 1H-pyrrolo[2,3-*c*]pyridine and tetrazole;

R^5 is selected from the group consisting of -carbocyclylR^7, -heterocyclylR^7, -arylR^7, -heteroarylR^7, and $-(C_{1\text{-}2}\ \text{alkyl})\text{heteroaryl}R^7$;

with the proviso that R^5 is not 4-pyridylR^7 when R^3 is selected from the group consisting of 3-pyridylR^6, 4-pyridylR^6, 2-pyridylR^6, phenylR^6, thiazoleR^6, imidazoleR^6, pyrimidineR^6, oxazoleR^6,  ,  ,  ,  ,

 ,  ,  ,  ,  , 

and  , and R^6 and R^7 are both H;

with the proviso that R^5 is not $-(CH_2)$(3-pyridyl)R^7 when R^3 is selected from the group consisting of 3-pyridylR^6, 4-pyridylR^6 and thiazoleR^6, and R^6 and R^7 are both H;

with the proviso that R^5 is not phenylR^7 when R^3 is 4-pyridylR^6 and R^6 and R^7 are both H;

with the proviso that R^3 is not 3-pyridylR^6 when R^5 is selected from the group consisting of phenylR^7,  ,  ,  ,  ,

 ,  ,  ,  ,  ,

 ,  ,  and  , and R^6 and R^7 are both H;

with the proviso that R^3 is not oxazoleR^6 when R^5 is selected from the group consisting of  ,  and  , and R^6 is H;

with the proviso that R^3 is not thiazoleR^6 when R^5 is selected from the group consisting of  and  , and R^6 is H;

each R^6 is 1-2 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, $-OCF_3$, $-CF_3$, -CN, $-OR^{10}$, -(C_{1-2} alkyl)heterocyclylR^8, -heterocyclylR^8, -(C_{1-2} alkyl)arylR^8, $-C(=O)R^{11}$, $-N(R^{10})C(=O)R^{11}$ and -(C_{1-2} alkyl)$N(R^{10})_2$;

each R^7 is 1-2 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, $-OCF_3$, $-CF_3$, -CN, $-OR^{10}$, -(C_{1-2} alkyl)heterocyclylR^9, -

heterocyclylR^9, -arylR^9, -(C_{1-2} alkyl)arylR^9, -C(=O)R^{11}, -N(R^{10})C(=O)R^{11}, -N(R^{10})$_2$, -(C_{1-2} alkyl)N(R^{10})$_2$, -N(R^{10})SO_2R^{11} and -SO_2R^{11};

each R^8 is 1-2 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, OCF_3, -CF_3 –CN and -OR^{12};

each R^9 is 1-2 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, -OCF_3, -CF_3 –CN and -OR^{12};

each R^{10} is independently selected from the group consisting of H, C_{1-3} alkyl, -(C_{1-3} alkyl)N(R^{14})$_2$ and -arylR^8;

each R^{11} is independently selected from the group consisting of C_{1-3} alkyl, -N(R^{14})$_2$, -carbocyclylR^8 and -heterocyclylR^8;

each R^{12} is independently selected from the group consisting of H and C_{1-3} alkyl;

each R^{14} is independently selected from the group consisting of H, C_{1-3} alkyl and carbocyclyl.

17. The compound of claim 1 having a structure selected from the group consisting of:


































































,

,

,

,

,

,

,

, and .

18. The compound of claim 17 having a structure selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,








,

,

,

,

,

, and

19. The compound of claim 17 having a structure selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,









, and .

20. The compound of claim 17 having a structure selected from the group consisting of:









, and

21. The compound of claim 17 having a structure selected from the group consisting of:









, and .

22. The compound of claim 17 having a structure selected from the group consisting of:











, and .

23. The compound of claim 17 having a structure selected from the group consisting of:
















, and .

24. The compound of claim 17 having a structure selected from the group consisting of:
























, and .

25. The compound of claim 17 having a structure selected from the group consisting of:








,

,

,

,

,

,

,

,

,

,

, and

.

26. The compound of claim 1 having a structure selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

, and
.

27. The compound of claim 26 having a structure selected from the group consisting of:


,

,

,

,

,

,

,

,

,

, and
.

28. The compound of claim 26 having a structure selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

, and
.

29. The compound of claim 26 having a structure selected from the group consisting of:


,

,

,

,

,

,

,

,

, and

.

30. The compound of claim 1 having a structure selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

, and
.

31. The compound of claim 30 having a structure selected from the group consisting of:


,

, and

.

32. The compound of claim 30 having a structure selected from the group consisting of:


,

, and

.

33. The compound of claim 30 having a structure selected from the group consisting of:

 ,  , and  .

34. The compound of claim 30 having a structure selected from the group consisting of:

 ,  , and  .

35. The compound of claim 30 having a structure selected from the group consisting of:

 ,  , and  .

36. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

37. Use of at least one compound according to claim 1, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a disorder or disease in which aberrant Wnt signaling is implicated in a patient.

38. A useof claim 37, wherein the disorder or disease is cancer.

39. A use of claim 37, wherein the disorder or disease is diabetic retinopathy.

40. A use of claim 37, wherein the disorder or disease is rheumatoid arthritis.

41. A use of claim 37, wherein the disorder or disease is a mycotic or viral infection.

42. A use of claim 37, wherein the disorder or disease is a bone or cartilage disease.

43. A use of claim 37, wherein the disorder or disease is a neurological condition, disorder or disease, wherein the neurological condition/disorder/disease is selected from: Alzheimer's disease, frontotemporal dementias, dementia with lewy bodies, prion diseases, Parkinson's disease, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, mutiple system atrophy, amyotrophic lateral sclerosis (ALS), inclusion body myositis, autism, degenerative myopathies, diabetic neuropathy, other metabolic neuropathies, endocrine neuropathies, orthostatic hypotension, multiple sclerosis and Charcot-Marie-Tooth disease.

44. A use of claim 37, wherein the disorder or disease is lung disease.

45. A use of claim 37, wherein the disorder or disease is osteoarthritis.

46. A use of claim 37, wherein the disorder or disease is a genetic disease caused by mutations in Wnt signaling components, wherein the genetic disease is selected from: polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia syndrome, Müllerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease and Rett syndrome.

47. A use of claim 37, wherein the disorder or disease is a fibrotic disorder, wherein the fibrotic disorder is selected from: skin fibrosis; scleroderma; progressive systemic fibrosis; lung fibrosis; muscle fibrosis; kidney fibrosis; glomerulosclerosis; glomerulonephritis; hypertrophic scar formation; uterine fibrosis; renal fibrosis; cirrhosis of the liver, liver fibrosis; adhesions, such as those occurring in the abdomen, pelvis, spine or tendons; chronic obstructive pulmonary disease; fibrosis following myocardial infarction; pulmonary fibrosis; fibrosis and scarring associated with diffuse/interstitial lung disease; central nervous system fibrosis, such as fibrosis following stroke; fibrosis

associated with neuro-degenerative disorders such as Alzheimer's Disease or multiple sclerosis; fibrosis associated with proliferative vitreoretinopathy (PVR); restenosis; endometriosis; ischemic disease and radiation fibrosis.

48. The use of claim 37, wherein the patient is a human.

49. The use of claim 38, wherein the cancer is chosen from: hepatocellular carcinoma, colon cancer, breast cancer, pancreatic cancer, chronic myeloid leukemia (CML), chronic myelomonocytic leukemia, chronic lymphocytic leukemia (CLL), acute myeloid leukemia, acute lymphocytic leukemia, Hodgkin lymphoma, lymphoma, sarcoma and ovarian cancer.

50. The use of claim 38, wherein the cancer is chosen from: lung cancer - non-small cell, lung cancer - small cell, multiple myeloma, nasopharyngeal cancer, neuroblastoma, osteosarcoma, penile cancer, pituitary tumors, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer - basal and squamous cell, skin cancer – melanoma, small intestine cancer, stomach cancers, testicular cancer, thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, laryngeal or hypopharyngeal cancer, kidney cancer, Kaposi sarcoma, gestational trophoblastic disease, gastrointestinal stromal tumor, gastrointestinal carcinoid tumor, gallbladder cancer, eye cancer (melanoma and lymphoma), Ewing tumor, esophagus cancer, endometrial cancer, colorectal cancer, cervical cancer, brain or spinal cord tumor, bone metastasis, bone cancer, bladder cancer, bile duct cancer, anal cancer and adrenal cortical cancer.

51. The use of claim 37, wherein the compound inhibits one or more proteins in the Wnt pathway.

52. The use of claim 51, wherein the compound inhibits signaling induced by one or more Wnt proteins.

53. The use of claim 52, wherein the Wnt proteins are chosen from: WNT1, WNT2, WNT2B, WNT3, WNT3A, WNT4. WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, and WNT16.

54. The use of claim 37, wherein the compound inhibits a kinase activity.

55. Use of at least one compound according to claim 1, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a disease or disorder mediated by the Wnt pathway in a patient.

56. The use of claim 55, wherein the compound inhibits one or more Wnt proteins.

57. Use of at least one compound according to claim 1, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a disease or disorder mediated by kinase activity in a patient.

58. The use of claim 57, wherein the disease or disorder comprises tumor growth, cell proliferation, or angiogenesis.

59. Use of at least one compound according to claim 1, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for inhibiting the activity of a protein kinase receptor, wherein the medicament is to be contacted with the receptor.

60. Use of at least one compound according to claim 1, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a disease or disorder associated with aberrant cellular proliferation in a patient.

61. Use of at least one compound according to claim 1, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for preventing or reducing angiogenesis in a patient.

62. Use of at least one compound according to claim 1, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for preventing or reducing abnormal cellular proliferation in a patient.

63. Use of a pharmaceutical composition comprising one or more of the compounds of claim 1 for the manufacture of a medicament for treating a disease or disorder associated with aberrant cellular proliferation in a patient, wherein the medicament is to be administered with a pharmaceutically acceptable carrier and one or more other agents.

WHAT IS CLAIMED IS:

1. A compound or pharmaceutically acceptable salt thereof having the structure of formula I:



I

wherein:

R^1, R^2 and R^4 are independently selected from the group consisting of H, C_{1-9} alkyl, halide, $-N(R^{10})_2$, $-XR^{10}$, CN, $-OCF_3$ and $-CF_3$;

R^3 is selected from the group consisting of carbocyclylR^6, arylR^6, 3-pyridylR^6, pyrimidinylR^6, pyridazinylR^6, and pyrazinylR^6;

R^5 is selected from the group consisting of $-(C_{1-9}$ alkyl$)_n$carbocyclylR^7, -piperazinylR^7, -tetrahydropyranylR^7, -pyrrolidinylR^7, -piperidinylR^7, -arylR^7, -3-pyridylR^7, -pyrimidinylR^7, -pyridazinylR^7, -pyrazolylR^7, -benzo[d][1,3]dioxolylR^7, 2,3-dihydrobenzo[b][1,4]dioxinylR^7, and -pyrazinylR^7;

with the proviso that R^3 is not 3-pyridylR^6 when R^1, R^2 and R^4 are H, R^5 is selected from the group consisting of phenylR^7,  ,  ,  , and  , and R^6 and R^7 are both H;

each R^6 is 1-5 substituents each selected from the group consisting of H, C_{1-9} alkyl, halide, amino, $-OCF_3$, $-CF_3$, -CN, $-XR^{10}$, $-(C_{1-9}$ alkyl$)_n$carbocyclylR^8, $-(C_{1-9}$ alkyl$)_n$heterocyclylR^8, $-(C_{1-9}$ alkyl)arylR^8, $-(C_{1-9}$ alkyl$)_n$heteroarylR^8, $-C(=O)R^{11}$, $-N(R^{10})C(=O)R^{11}$, $-(C_{1-9}$ alkyl$)_nN(R^{10})_2$, $-(C_{1-9}$ alkyl$)_nN(R^{10})SO_2R^{11}$ and $-SO_2R^{11}$;

each R^7 is 1-5 substituents each selected from the group consisting of H, C_{1-9} alkyl, halide, amino, $-OCF_3$, $-CF_3$, -CN, $-XR^{10}$, $-(C_{1-9}$ alkyl$)_n$carbocyclylR^9, $-(C_{1-9}$ alkyl$)_n$heterocyclylR^9, $-(C_{1-9}$ alkyl$)_n$arylR^9, $-(C_{1-9}$ alkyl$)_n$heteroarylR^9, $-C(=O)R^{11}$, $-N(R^{10})C(=O)R^{11}$, $-(C_{1-9}$ alkyl$)_nN(R^{10})_2$, and $-SO_2R^{11}$;

each R^8 is 1-5 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, OCF_3, $-CF_3$ -CN, $-XR^{12}$, $-C(=O)R^{13}$, $-N(R^{12})C(=O)R^{13}$, $-(C_{1-9}\text{ alkyl})_nN(R^{12})_2$, $-(C_{1-9}\text{ alkyl})_nN(R^{12})SO_2R^{13}$ and $-SO_2R^{13}$;

each R^9 is 1-5 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, $-OCF_3$, $-CF_3$ -CN, $-XR^{12}$, $-C(=O)R^{13}$, $-N(R^{12})C(=O)R^{13}$, $-(C_{1-9}\text{ alkyl})_nN(R^{12})_2$, $-(C_{1-9}\text{ alkyl})_nN(R^{12})SO_2R^{13}$ and $-SO_2R^{13}$;

each R^{10} is independently selected from the group consisting of H, C_{1-9} alkyl, $-(C_{1-9}\text{ alkyl})_nN(R^{14})_2$, $-(C_{1-9}\text{ alkyl})_n$carbocyclyl$R^8$, $-(C_{1-9}\text{ alkyl})_n$heterocyclyl$R^8$, $-(C_{1-9}\text{ alkyl})_n$aryl$R^8$ and $-(C_{1-9}\text{ alkyl})_n$heteroaryl$R^8$;

each R^{11} is independently selected from the group consisting of C_{1-9} alkyl, $-(C_{1-9}\text{ alkyl})_n$carbocyclyl$R^8$, $-(C_{1-9}\text{ alkyl})_n$heterocyclyl$R^8$, $-(C_{1-9}\text{ alkyl})_n$aryl$R^8$ and $-(C_{1-9}\text{ alkyl})_n$heteroaryl$R^8$;

each R^{12} is independently selected from the group consisting of H, C_{1-9} alkyl, $-(C_{1-9}\text{ alkyl})_nN(R^{14})_2$, $-(C_{1-9}\text{ alkyl})_n$carbocyclyl, $-(C_{1-9}\text{ alkyl})_n$heterocyclyl, $-(C_{1-9}\text{ alkyl})_n$aryl and $-(C_{1-9}\text{ alkyl})_n$heteroaryl;

each R^{13} is independently selected from the group consisting of C_{1-9} alkyl, $-N(R^{14})_2$, $-(C_{1-9}\text{ alkyl})_n$carbocyclyl, $-(C_{1-9}\text{ alkyl})_n$heterocyclyl, $-(C_{1-9}\text{ alkyl})_n$aryl and $-(C_{1-9}\text{ alkyl})_n$heteroaryl;

each R^{14} is independently selected from the group consisting of H, C_{1-3} alkyl, carbocyclyl and aryl;

each X is selected from the group consisting of a bond, -O- and -S-; and

each n is 0 or 1.

2. The compound of claim 1 wherein n is 0.

3. The compound of claim 1 wherein n is 1.

4. The compound of claim 1 wherein X is O.

5. The compound of claim 1 wherein R^1, R^2 and R^4 are H.

6. The compound of claim 1 wherein R^3 is selected from the group consisting of 3-pyridylR^6, pyrimidinylR^6, pyridazinylR^6, and pyrazinylR^6.

7. The compound of claim 6 wherein the R^3 is 3-pyridylR^6.

8. The compound of claim 6 wherein the R^3 is 5-pyrimidinylR^6.

9. The compound of claim 6 wherein the R^3 is 4-pyridazinylR^6.

10. The compound according to any one of claims 1-9, wherein R^6 is one substituent and is selected from the group consisting of H and $-N(R^{10})C(=O)R^{11}$.

11. The compound according to any one of claims 1-10, wherein R^5 is selected from the group consisting of -3-pyridylR^7, -pyrimidinylR^7, -pyridazinylR^7, -pyrazolylR^7, -benzo[d][1,3]dioxolylR^7, 2,3-dihydrobenzo[b][1,4]dioxinylR^7, and -pyrazinylR^7.

12. The compound according to any one of claims 1-11, wherein the R^5 is 3-pyridylR^7.

13. The compound according to any one of claims 1-11, wherein the R^5 is 5-pyrimidinylR^7.

14. The compound according to any one of claims 1-11, wherein the R^5 is 4-pyridazinylR^7.

15. The compound according to any one of claims 1-14, wherein R^7 is one substituent and is selected from the group consisting of H, halide, $-OCF_3$, $-CF_3$, $-(C_{1-9}\text{ alkyl})_n\text{heterocyclyl}R^9$, $-(C_{1-9}\text{ alkyl})_nN(R^{10})_2$, and $-N(R^{10})C(=O)R^{11}$.

16. A compound or pharmaceutically acceptable salt thereof having the structure of formula **Ia**:



Ia

wherein:

R^3 is selected from the group consisting of arylR^6 and 3-pyridylR^6;

R^5 is selected from the group consisting of -arylR^7, -3-pyridylR^7, -pyrimidinylR^7, -pyridazinylR^7, and -pyrazinylR^7;

with the proviso that R^3 is not 3-pyridylR^6 when R^1, R^2 and R^4 are H, R^5 is selected from the group consisting of phenylR^7, 

, 

, 

, and 

, and R^6 and R^7 are both H;

each R^6 is 1-2 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, $-OCF_3$, $-CF_3$, -CN, $-OR^{10}$, -(C_{1-2} alkyl)heterocyclylR^8, -heterocyclylR^8, -(C_{1-2} alkyl)arylR^8, $-C(=O)R^{11}$, $-N(R^{10})C(=O)R^{11}$ and -(C_{1-2} alkyl)$N(R^{10})_2$;

each R^7 is 1-2 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, $-OCF_3$, $-CF_3$, -CN, $-OR^{10}$, -(C_{1-2} alkyl)heterocyclylR^9, -heterocyclylR^9, -arylR^9, -(C_{1-2} alkyl)arylR^9, $-C(=O)R^{11}$, $-N(R^{10})C(=O)R^{11}$, $-N(R^{10})_2$, -(C_{1-2} alkyl)$N(R^{10})_2$, $-N(R^{10})SO_2R^{11}$ and $-SO_2R^{11}$;

each R^8 is 1-2 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, OCF_3, $-CF_3$ –CN and $-OR^{12}$;

each R^9 is 1-2 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, $-OCF_3$, $-CF_3$ –CN and $-OR^{12}$;

each R^{10} is independently selected from the group consisting of H, C_{1-3} alkyl, -(C_{1-3} alkyl)$N(R^{14})_2$ and -arylR^8;

each R^{11} is independently selected from the group consisting of C_{1-3} alkyl, $-N(R^{14})_2$, -carbocyclylR^8 and -heterocyclylR^8;

each R^{12} is independently selected from the group consisting of H and C_{1-3} alkyl;

each R^{14} is independently selected from the group consisting of H, C_{1-3} alkyl and carbocyclyl.

17. The compound of claim 1 having a structure selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

, and

, or a pharmaceutically acceptable salt thereof.

18. The compound of claim 17 having a structure selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



19. The compound of claim 17 having a structure selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


, 
, and 
, or a pharmaceutically acceptable salt thereof..

20. The compound of claim 17 having a structure selected from the group consisting of:


, 
, 
, 
,


, 
, 
, 
,


, 
, 
, 
,


, 
, 
, 
,


, 
,
,

,
, 
,
,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

, and

, or a pharmaceutically acceptable salt thereof..

21. The compound of claim 17 having a structure selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

, and , or a pharmaceutically acceptable salt thereof.

22. The compound of claim 17 having a structure selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

, and

, or a pharmaceutically acceptable salt thereof.

23. The compound of claim 17 having a structure selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

and , or a pharmaceutically acceptable salt thereof.

24. The compound of claim 17 having a structure selected from the group consisting of:


,

,

,

,

,

,

,

,




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

, and

, or a pharmaceutically acceptable salt thereof.

25. The compound of claim 17 having a structure selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

, and

, or a pharmaceutically acceptable salt thereof.

26. The compound of claim 1 having a structure selected from the group consisting of:



27. The compound of claim 26 having a structure selected from the group consisting of:


,

,

,

,

,

,

,

,

,

, and

, or a pharmaceutically acceptable salt thereof.

28. The compound of claim 26 having a structure selected from the group consisting of:


,

,

,

,

,

,

,

, and

, or a pharmaceutically acceptable salt thereof.

29. The compound of claim 26 having a structure selected from the group consisting of:


,

,

,

,

,

,

, and

, or a pharmaceutically acceptable salt thereof.

30. The compound of claim 1 having a structure selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

,

, and

, or a pharmaceutically acceptable salt thereof.

31. The compound of claim 30 having a structure selected from the group consisting of:

 ,  , and  , or a pharmaceutically acceptable salt thereof.

32. The compound of claim 30 having a structure selected from the group consisting of:

 ,  , and  , or a pharmaceutically acceptable salt thereof.

33. The compound of claim 30 having a structure selected from the group consisting of:

 ,  , and  , or a pharmaceutically acceptable salt thereof.

34. The compound of claim 30 having a structure selected from the group consisting of:

 ,  , and  , or a pharmaceutically acceptable salt thereof.

35. The compound of claim 30 having a structure selected from the group consisting of:

 ,  , and  , or a pharmaceutically acceptable salt thereof.

36. A compound having the structure of:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

, and

, or a pharmaceutically acceptable salt thereof.

37. The compound of claim 1, wherein the structure of Formula **Ia** is:



Ia

or a pharmaceutically acceptable salt thereof,

wherein:

R^3 is 3-pyridylR^6;

R^5 is selected from the group consisting of pyridylR^7, -pyrimidinylR^7, and -pyridazinylR^7;

R^6 is $-CH_2$heterocyclylR^8;

R^7 is 1-2 substituents each independently selected from the group consisting of H, F, methyl, $-NH_2$, $-CF_3$, -CN, -OMe, $-SO_2Me$,  , and  ;

R^8 is 1-2 substituents each independently selected from the group consisting of H and halide.

38. The compound of claim 37, wherein the R^6 heterocyclyl is selected from the group consisting of azetidinylR^8, pyrrolidinylR^8, piperidinylR^8, piperazinylR^8, and morpholinylR^8.

39. The compound of claim 37, wherein R^6 is $-CH_2$piperidinylR^8.

40. The compound of claim 37, wherein R^7 is selected from the group consisting of H, -CF_3, -OMe, -CN,  , and .

41. The compound according to any one of claims 37-40, wherein R^8 is H.

42. The compound of claim 37 having a structure of:

 , or a pharmaceutically acceptable salt thereof.

43. The compound of claim 37 having a structure of:

 , or a pharmaceutically acceptable salt thereof.

44. The compound of claim 37 having a structure of:



, or a pharmaceutically acceptable salt thereof.

45. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

46. Use of at least one compound according to claim 1, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a disorder or disease in which aberrant Wnt signaling is implicated in a patient.

47. A use of claim 46, wherein the disorder or disease is cancer.

48. A use of claim 46, wherein the disorder or disease is diabetic retinopathy.

49. A use of claim 46, wherein the disorder or disease is rheumatoid arthritis.

50. A use of claim 46, wherein the disorder or disease is a mycotic or viral infection.

51. A use of claim 46, wherein the disorder or disease is a bone or cartilage disease.

52. A use of claim 46, wherein the disorder or disease is a neurological condition, disorder or disease, wherein the neurological condition/disorder/disease is selected from: Alzheimer's disease, frontotemporal dementias, dementia with lewy bodies, prion diseases, Parkinson's disease, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, amyotrophic lateral sclerosis (ALS), inclusion body myositis, autism, degenerative myopathies, diabetic neuropathy, other metabolic neuropathies, endocrine neuropathies, orthostatic hypotension, multiple sclerosis and Charcot-Marie-Tooth disease.

53. A use of claim 46, wherein the disorder or disease is lung disease.

54. A use of claim 46, wherein the disorder or disease is osteoarthritis.

55. A use of claim 46, wherein the disorder or disease is a genetic disease caused by mutations in Wnt signaling components, wherein the genetic disease is selected from: polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia syndrome, Müllerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas-

Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease and Rett syndrome.

56. A use of claim 46, wherein the disorder or disease is a fibrotic disorder, wherein the fibrotic disorder is selected from: skin fibrosis; scleroderma; progressive systemic fibrosis; lung fibrosis; muscle fibrosis; kidney fibrosis; glomerulosclerosis; glomerulonephritis; hypertrophic scar formation; uterine fibrosis; renal fibrosis; cirrhosis of the liver, liver fibrosis; adhesions, such as those occurring in the abdomen, pelvis, spine or tendons; chronic obstructive pulmonary disease; fibrosis following myocardial infarction; pulmonary fibrosis; fibrosis and scarring associated with diffuse/interstitial lung disease; central nervous system fibrosis, such as fibrosis following stroke; fibrosis associated with neuro-degenerative disorders such as Alzheimer's Disease or multiple sclerosis; fibrosis associated with proliferative vitreoretinopathy (PVR); restenosis; endometriosis; ischemic disease and radiation fibrosis.

57. The use of claim 46, wherein the patient is a human.

58. The use of claim 47, wherein the cancer is chosen from: hepatocellular carcinoma, colon cancer, breast cancer, pancreatic cancer, chronic myeloid leukemia (CML), chronic myelomonocytic leukemia, chronic lymphocytic leukemia (CLL), acute myeloid leukemia, acute lymphocytic leukemia, Hodgkin lymphoma, lymphoma, sarcoma and ovarian cancer.

59. The use of claim 47, wherein the cancer is chosen from: lung cancer - non-small cell, lung cancer - small cell, multiple myeloma, nasopharyngeal cancer, neuroblastoma, osteosarcoma, penile cancer, pituitary tumors, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer - basal and squamous cell, skin cancer – melanoma, small intestine cancer, stomach cancers, testicular cancer, thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, laryngeal or hypopharyngeal cancer, kidney cancer, Kaposi sarcoma, gestational trophoblastic disease, gastrointestinal stromal tumor, gastrointestinal carcinoid tumor, gallbladder cancer, eye cancer (melanoma and lymphoma), Ewing tumor, esophagus cancer, endometrial cancer, colorectal cancer, cervical cancer, brain or spinal cord tumor, bone metastasis, bone cancer, bladder cancer, bile duct cancer, anal cancer and adrenal cortical cancer.

60. The use of claim 46, wherein the compound inhibits one or more proteins in the Wnt pathway.

61. The use of claim 60, wherein the compound inhibits signaling induced by one or more Wnt proteins.

62. The use of claim 61, wherein the Wnt proteins are chosen from: WNT1, WNT2, WNT2B, WNT3, WNT3A, WNT4. WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, and WNT16.

63. The use of claim 46, wherein the compound inhibits a kinase activity.

64. Use of at least one compound according to claim 1, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a disease or disorder mediated by the Wnt pathway in a patient.

65. The use of claim 64, wherein the compound inhibits one or more Wnt proteins.

66. Use of at least one compound according to claim 1, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a disease or disorder mediated by kinase activity in a patient.

67. The use of claim 66, wherein the disease or disorder comprises tumor growth, cell proliferation, or angiogenesis.

68. Use of at least one compound according to claim 1, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for inhibiting the activity of a protein kinase receptor, wherein the medicament is to be contacted with the receptor.

69. Use of at least one compound according to claim 1, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a disease or disorder associated with aberrant cellular proliferation in a patient.

70. Use of at least one compound according to claim 1, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for preventing or reducing angiogenesis in a patient.

71. Use of at least one compound according to claim 1, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for preventing or reducing abnormal cellular proliferation in a patient.

72. Use of a pharmaceutical composition comprising one or more of the compounds of claim 1 for the manufacture of a medicament for treating a disease or disorder associated with

aberrant cellular proliferation in a patient, wherein the medicament is to be administered with a pharmaceutically acceptable carrier and one or more other agents.